1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Dr. Cortes is a clinical research scholar for The Leukemia and Lymphoma Society, White Plains, New York.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders†
Article first published online: 19 MAY 2003
DOI: 10.1002/cncr.11416
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Cortes, J., Giles, F., O'Brien, S., Thomas, D., Albitar, M., Rios, M. B., Talpaz, M., Garcia-Manero, G., Faderl, S., Letvak, L., Salvado, A. and Kantarjian, H. (2003), Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 97: 2760–2766. doi: 10.1002/cncr.11416
- †
Dr. Armand Keating served as guest editor on this article.
Publication History
- Issue published online: 19 MAY 2003
- Article first published online: 19 MAY 2003
- Manuscript Accepted: 27 FEB 2003
- Manuscript Revised: 24 FEB 2003
- Manuscript Received: 13 DEC 2002
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , Activated leukemic oncogenes AML1-ETO and c-kit: Role in development of acute myeloid leukemia and current approaches for their inhibition, Biochemistry (Moscow), 2011, 75, 13, 1650
- 2, , , , , , Gene Mutations, Epigenetic Dysregulation, and Personalized Therapy in Myeloid Neoplasia: Are We There Yet?, Seminars in Oncology, 2011, 38, 2, 196
- 3, , , , , , , , A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis, Sarcoma, 2010, 2010, 1
- 4, , , Clinical implications of c-Kit mutations in acute myelogenous leukemia, Current Hematologic Malignancy Reports, 2009, 4, 2, 77
- 5, , Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly, Cancer Treatment Reviews, 2009, 35, 2, 97
- 6, Preclinical and clinical experience with dasatinib in philadelphia chromosome-negative leukemias and myeloid disorders, Leukemia Research, 2009, 33, 5, 617
- 7, , , , , , , , , , An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation, Leukemia Research, 2008, 32, 6, 936
- 8, , , Deregulation of Signaling Pathways in Acute Myeloid Leukemia, Seminars in Oncology, 2008, 35, 4, 336
- 9
- 10, , , , , , , , , , Successful Treatment of Chronic Myeloproliferative Disease-unclassifiable (CMPD-U) with No Chromosomal Abnormalities by Imatinib Mesylate, Internal Medicine, 2008, 47, 8, 791
- 11, , , Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia, Current Treatment Options in Oncology, 2007, 8, 2, 117
- 12, , Exploiting Signal Transduction Pathways in Acute Myelogenous Leukemia, Current Treatment Options in Oncology, 2007, 8, 4, 265
- 13, , , Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate, Leukemia, 2007, 21, 3, 577
- 14, Myelofibrosis: biology and treatment options, European Journal of Haematology, 2007, 79,Direct Link:
- 15, Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders, Hematology, 2007, 2007, 1, 355
- 16, , , , , , , , , , Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib, Cancer, 2007, 109, 5Direct Link:
- 17, , , Targeting receptor tyrosine kinase signaling in acute myeloid leukemia, Critical Reviews in Oncology/Hematology, 2007, 63, 3, 215
- 18, , A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders, Leukemia & Lymphoma, 2006, 47, 3, 381
- 19, , , , , , , , , Acute monocytic leukemia with coexpression of minor BCR–ABL1 and PICALM–MLLT10 fusion genes along with overexpression of HOXA9, Genes, Chromosomes and Cancer, 2006, 45, 6Direct Link:
- 20, , , , , , , , , , , , , , , Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study, European Journal of Haematology, 2006, 76, 1Direct Link:
- 21, , , Biology of Platelet-Derived Growth Factor and Its Involvement in Disease, Mayo Clinic Proceedings, 2006, 81, 9, 1241
- 22, , , , , , , , Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes?, Future Oncology, 2006, 2, 3, 407
- 23, , , , , , Identification of c-Kit gene mutations in patients with polycythemia vera, Leukemia Research, 2006, 30, 10, 1325
- 24, , , , , , , , , , Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome, Cancer, 2006, 106, 5Direct Link:
- 25, , Mutation de la protéine kinase JAK2 au cours de la polyglobulie de Vaquez : nouvelles perspectives physiopathologiques et thérapeutiques, La Revue de Médecine Interne, 2006, 27, 6, 473
- 26, , , , , Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options, Best Practice & Research Clinical Haematology, 2006, 19, 3, 495
- 27, , New agents in myelodysplastic syndromes, Current Hematologic Malignancy Reports, 2006, 1, 1, 25
- 28, Targeting the c-kit receptor in the treatment of acute myelogenous leukemia, Current Hematologic Malignancy Reports, 2006, 1, 2, 101
- 29, , , , , , , , , , , , Thalidomide therapy for myelofibrosis with myeloid metaplasia, Cancer, 2006, 106, 9Direct Link:
- 30, , The Myelodysplastic Syndromes: Diagnosis and Treatment, Mayo Clinic Proceedings, 2006, 81, 1, 104
- 31, , , , , , , , , , , , , , , Long-term follow-up of a patient with idiopathic myelofibrosis associated with chromosome 11 and 13 abnormalities, American Journal of Hematology, 2005, 78, 1Direct Link:
- 32, Modern management of myelofibrosis, British Journal of Haematology, 2005, 128, 5Direct Link:
- 33, , , , , New approaches in the treatment of myelofibrosis, Cancer, 2005, 103, 1Direct Link:
- 34, , , , , , Trends in the Treatment of Acute Myeloid Leukaemia in the Elderly, Drugs & Aging, 2005, 22, 11, 943
- 35
- 36, , , , Accelerated and blastic phases of chronic myelogenous leukemia, Hematology/Oncology Clinics of North America, 2004, 18, 3, 753
- 37, , Beyond chronic myelogenous leukemia, Cancer, 2004, 100, 10Direct Link:
- 38, Inhibitors of signaling in myelodysplastic syndrome, Best Practice & Research Clinical Haematology, 2004, 17, 4, 613
- 39, Myelodysplastic syndromes: from pathogenesis and prognosis to treatment, Seminars in Hematology, 2004, 41, 6
- 40, , , , New agents in acute myeloid leukemia and other myeloid disorders, Cancer, 2004, 100, 3Direct Link:
- 41, , Novel therapies for myelodysplastic syndromes, Cancer, 2004, 101, 2Direct Link:
- 42, , Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia, British Journal of Haematology, 2004, 127, 3Direct Link:
- 43, , , , , Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate, European Journal of Haematology, 2004, 73, 2Direct Link:
- 44
- 45
- 46
- 47
- 48Current Awareness in Hematological Oncology, Hematological Oncology, 2003, 21, 4Direct Link: